---
title: "CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277929926.md"
description: "CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China"
datetime: "2026-03-05T11:53:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277929926.md)
  - [en](https://longbridge.com/en/news/277929926.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277929926.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/277929926.md) | [繁體中文](https://longbridge.com/zh-HK/news/277929926.md)


# CSPC Pharmaceutical says indacaterol acetate and mometasone furoate powder for inhalation obtains clinical trial approval in China



### Related Stocks

- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/en/quote/513700.CN.md)
- [CSPC PHARMA (01093.HK)](https://longbridge.com/en/quote/01093.HK.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/en/quote/513120.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/en/quote/520880.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/en/quote/513060.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/en/quote/516930.CN.md)
- [Hwabao WP CSI Pharmaceuticals ETF (562050.CN)](https://longbridge.com/en/quote/562050.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/en/quote/588130.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/en/quote/159837.CN.md)
- [China Universal CNI HK Connect Innovative Drugs Industry ETF (159570.CN)](https://longbridge.com/en/quote/159570.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/en/quote/159506.CN.md)
- [CSPC Innovation (300765.CN)](https://longbridge.com/en/quote/300765.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/en/quote/159892.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/en/quote/159849.CN.md)
- [Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII) (520500.CN)](https://longbridge.com/en/quote/520500.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/en/quote/159316.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/en/quote/512010.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/en/quote/516500.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/en/quote/159992.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/en/quote/510660.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/en/quote/512290.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/en/quote/520690.CN.md)

## Related News & Research

- [Henlius Biotech Doses First Patient in Phase 2/3 Breast Cancer Drug Study; Shares Slip 3%](https://longbridge.com/en/news/277421361.md)
- [03:03 ETSectra acquires Oxipit, advancing autonomous AI capabilities in diagnostic imaging](https://longbridge.com/en/news/277900089.md)
- [These Analysts Cut Their Forecasts On Veeva Systems Following Q4 Results](https://longbridge.com/en/news/277930677.md)
- [Sanofi bets on Sino Biopharm’s transplant drug in $1.5bn licensing deal](https://longbridge.com/en/news/277818646.md)
- [Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 billion](https://longbridge.com/en/news/277695972.md)